Comparison Between Efficacy of Triamcinolone Acetonide and Bevacizumab in a Case with Type 2A Idiopathic Parafoveal Telangiectasia

Raza, Sabri; Toklu, Yasin; Anayol, Mustafa Alpaslan; Şimşek, Şaban; Özkan, Bülent; Altıntaş, Ayşegül Koçak

doi:10.4274/tjo.41.02

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,15,16,17,18,19,20,21,22 In some of these studies, however, the leakage on FA was reported to return to baseline levels during periods without injections. 15,17,20,22 Similarly, though decreases in macular thickness measured by OCT may be detected initially, 12,16,17,18,19,20,21,22,24 studies with long-term follow-up after the final injection reported that OCT findings also returned to baseline. 17,18,20,22 Besides these studies, there are others in which no substantial changes in OCT findings were observed.…”

Section: Discussionmentioning

confidence: 98%

“…13,14,15 Results concerning visual acuity vary. Some studies show improvements in visual acuity, 12,18,19,20,22 whereas others report no change or even decline over time. 13,14,15,16,20,22,24 Response to treatment varies in terms of disease duration and severity, and degree of neuroretinal degeneration.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, intravitreal anti-vascular endothelial growth factor (VEGF) injection has been administered to proliferative and nonproliferative patient groups in a variety of studies. 12,13,14,15,16,17,18,19,20,21,22,23,24 Although the results of these studies differ, some patients reportedly benefited from intravitreal anti-VEGF injections.…”

Section: Introductionmentioning

confidence: 99%

“…Various treatments such as focal/grid argon laser therapy, 7 transpupillary thermotherapy, 8 photodynamic therapy, 9 subretinal membrane surgical excision, 10 and intravitreal triamcinolone 11,12 have been tried in type 2 IMT patients. In recent years, intravitreal anti-vascular endothelial growth factor (VEGF) injection has been administered to proliferative and nonproliferative patient groups in a variety of studies.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

Aydoğan

Erdoğan

Ünlü

et al. 2016

tjo

View full text Add to dashboard Cite

Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT).Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were included in this study. All the patients had an ophthalmological examination including best corrected visual acuity (BCVA), dilated fundus examination, spectral domain optical coherence tomography (OCT) and fluorescein angiography. Intravitreal bevacizumab injection was planned for patients who had macular edema and/or decreased visual acuity at baseline. Patients were examined 1 week and 1 month after the intravitreal injection. Intravitreal injection was repeated in patients whose visual acuity decreased and/or whose macular edema persisted or increased. Changes in BCVA, central macular thickness (CMT) and central macular volume from baseline at 1 month after the first injection and at final examination were evaluated.Results: Average age of the patients (4 female and 1 male) was 62±11.8 years. Average follow-up period was 26±11 months. Patients received an average of 2.3 (range 1-4) injections during follow-up. Average Snellen BCVA of the patients was 0.48±0.29. BCVA increased at final examination compared to baseline in all of the patients. The difference between baseline and final visual acuities was significant (p<0.05). The patients’ average CMT was 328±139 µm at baseline and decreased by a mean of 85±153 µm at 1 month after the first injection and 65±142 µm at final examination, but the changes were not significant. CMT decreased at final examination compared to baseline in four patients and increased in both eyes of one patient.Conclusion: Intravitreal bevacizumab injection is a preferable treatment method in regard to both visual acuity and OCT findings.

show abstract